Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study

• Published in: PloS one Vol. 11; no. 4; p. e0153227
• Main Authors: Ji, Jun, Wang, Hao, Li, Yan, Zheng, Lei, Yin, Yuepeng, Zou, Zhenzhen, Zhou, Feiguo, Zhou, Weiping, Shen, Feng, Gao, Chunfang
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 12.04.2016; Public Library of Science (PLoS)
• Subjects: alpha-Fetoproteins - metabolism; Biology and Life Sciences; Biomarkers - blood; Biomarkers, Tumor - blood; Carcinoma, Hepatocellular - blood; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - etiology; Case-Control Studies; Cell growth; Cell survival; Cirrhosis; Cohort Studies; Diagnostic systems; Exploration; Female; Health care facilities; Hemangioma - blood; Hemangioma - diagnosis; Hepatitis; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic - complications; Hepatocellular carcinoma; Histopathology; Hospitals; Humans; Laboratories; Liver; Liver cancer; Liver cirrhosis; Liver Cirrhosis - blood; Liver Cirrhosis - diagnosis; Liver diseases; Liver Neoplasms - blood; Liver Neoplasms - diagnosis; Liver Neoplasms - etiology; Male; Medical diagnosis; Medicine; Medicine and Health Sciences; Metastases; Metastasis; Neoplasm Metastasis - diagnosis; Patients; Prognosis; Protein Precursors - blood; Prothrombin; Studies; Surgery; Surveillance; Ultrasonic imaging; Viruses
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0153227

An efficient serum marker for hepatocellular carcinoma (HCC) is currently lacking and requires intensive exploration. We aimed to evaluate the performance of des-gamma-carboxy prothrombin (DCP) for identifying hepatitis B virus-related HCC in a large, multicentre study in China. A total of 1034 subjects in three cohorts (A, B, and C) including HCC and various non-HCC controls were enrolled from 4 academic medical centers in China from January 2011 to February 2014. Blind parallel detections were conducted for DCP and AFP. The area under the receiver operating characteristic curve (AUC) was used to evaluate the diagnostic efficacies. In cohort A, which comprised 521 subjects, including patients with HCC, liver metastasis, liver cirrhosis (LC), and liver hemangiomas as well as healthy controls (HCs), the accuracy of DCP for distinguishing HCC from various controls was 6.2-9.7% higher than that of AFP. In cohort B, which comprised 447 subjects, including patients with HCC, LC, and chronic hepatitis B as well as HC, the accuracy of DCP was further elevated (12.3-20.67% higher than that of AFP). The superiority of DCP to AFP was more profound in the surveillance of early HCC [AUC 0.837 (95% CI: 0.771-0.903) vs. 0.650 (0.555-0.745)] and AFP-negative HCC [AUC: 0.856 (0.798-0.914)] and in discriminating HCC from LC (accuracy: 92.9% vs.64.71%). Higher DCP levels were associated with worse clinical behaviors and shorter disease-free survival. DCP not only is complementary to AFP in identifying AFP-negative HCC and in excluding AFP-positive non-HCC (liver cirrhosis), but also demonstrates improved performance in HCC surveillance, early diagnosis, treatment response and recurrence monitoring in the HBV-related population.